PP
IMDX

Paloma Partners’s Insight Molecular Diagnostics IMDX Stock Holding History

Paloma Partners’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-539
Closed -$27K – 1829
2018
Q2 		$27K Buy
+539
New +$26.6K ﹤0.01% 1562
2016
Q3 		– Sell
-588
Closed -$42K – 2043
2016
Q2 		$42K Buy
+588
New +$55K ﹤0.01% 2110

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $3.85B AUM 13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Paloma Partners's IMDX Position: Q3 2018 in Review

Paloma Partners sold out of Insight Molecular Diagnostics (IMDX) in Q3 2018, closing a stake of 539 shares — an estimated $27K sold.

Paloma Partners first reported a position in IMDX in Q2 2016 and held it in 2 quarters. The position peaked at $42K in Q2 2016. 26 funds tracked by Wall St. Rank hold IMDX as of Q3 2018.

  • Paloma Partners reported no remaining Insight Molecular Diagnostics position as of Q3 2018 after selling out during the quarter.
  • Paloma Partners sold 539 Insight Molecular Diagnostics shares in Q3 2018, an estimated $27K.
  • Paloma Partners first reported a position in Insight Molecular Diagnostics in Q2 2016 and held it in 2 quarters.
  • Paloma Partners's Insight Molecular Diagnostics position peaked at $42K in Q2 2016.
  • 26 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2018.

Based on Paloma Partners's 13F filing for Q3 2018, filed 14 Nov 2018.